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Abstract 
Context: The origin of Graves disease (GD) remains elusive. However, evidence of an 
association between GD and viral infections is emerging. Human leukocyte antigen 
(HLA) class I presents viral antigens to circulating immune cells and plays a crucial role 
in the defense against viral infections.
Objective: This work aimed to investigate HLA class I expression, enterovirus presence, 
and the viral immune response proteins signal transducer and activation of transcription 
1 (STAT1) and protein kinase R (PKR) in thyroid tissue from GD patients.
Methods: We collected thyroid tissue from core needle biopsies or surgical specimens 
from 48 GD patients and 24 controls. Standard immunohistochemistry was used to 
detect HLA class I and enteroviral capsid protein 1 (VP1) on formalin-fixed and paraffin-
embedded tissue. STAT1 and PKR were examined by combined immunofluorescence 
staining. HLA class I expression score was the main outcome measure.
Results: The HLA class  I  expression score, which takes both proportion and intensity of 
immunostaining into account, was significantly higher in GD patients (3.1 ± 3.3) than in 
controls (0.5 ± 0.9) (P < .001). Significantly more VP1 positive thyroid cells were found GD 
samples (50.1 ± 30.5%) than in controls (14.9 ± 10.5%) (P < .001). STAT1 and HLA class I were 
found within the same thyroid cells and PKR and VP1 were also colocalized within thyroid cells.
Conclusion: HLA class  I  is upregulated in GD and enterovirus protein is prevalent in 
thyroid tissue. The colocalization of HLA class I with STAT1 and VP1 with PKR indicates 
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Graves disease (GD) is a prevalent, autoimmune endocrine 
disease, caused by an interplay between genetic and envir-
onmental factors (1, 2). The incidence of GD shows seasonal 
trends and variable geographical distribution, indicating 
possible epidemic triggering factors (3). Evidence of an as-
sociation between viral infections and autoimmune thyroid 
disease (AITD) is emerging (4-11). Enterovirus, in particular, 
has been linked to numerous autoimmune diseases, and the 
association with type 1 diabetes is especially strong (12-15).
The class  I major histocompatibility complex, usually 
known as human leukocyte antigen (HLA) class  I  in hu-
mans, is a complex of molecules expressed on nucleated 
cells. HLA class I normally presents peptides from intra-
cellular host proteins. During viral infections, HLA class 
I presents viral antigens on the cell surface, which is vital 
for recognition and destruction of infected cells by CD8⁺ T 
cells (cytotoxic T cells). By contrast, HLA class II presents 
with extracellular pathogens, such as bacteria.
Antigen presentation is possibly a key process in inducing 
thyroid autoimmunity. An association between aberrant 
HLA class II expression and thyroid autoimmunity is recog-
nized (16), and the HLA class  II gene variant HLA-DR3is 
a major AITD susceptibility gene (17-19). HLA class I and 
its role in thyroid autoimmunity, on the other hand, is less 
explored. However, HLA class I alleles have been linked to 
AITD (20, 21), and our group recently reported that HLA 
class I is upregulated in Hashimoto thyroiditis (22).
HLA class  I  is upregulated in response to interferon-
activated signal transducer and activator of transcription 1 
(STAT1) (23). Moreover, STAT1 promotes transcription of 
several genes involved in antiviral defense mechanisms, one 
of which is protein kinase R (PKR) (24-30), an enzyme that 
inhibits viral protein synthesis (31, 32).
To further investigate the association between viral in-
fection and thyroid autoimmunity, we aimed to i) examine 
the expression of HLA class  I  in thyroid cells in GD, ii) 
examine the presence of the antiviral immune response pro-
teins STAT1 and PKR in GD, and iii) confirm the presence 
of enterovirus in GD. Using immunohistochemistry (IHC) 
and combined immunofluorescence (IF), we evaluated the 
expression of HLA class  I, STAT1, PKR, and enteroviral 
capsid protein 1 (VP1) in thyroid tissue from a cohort of 
both recent-onset and chronic GD.
Material and Methods
Study participants and thyroid tissue collection
For this study, we used previously collected thyroid tissue 
samples from 48 patients with GD and 24 controls at Oslo 
University Hospital (11). Age, sex, smoking habits, thy-
roid function, disease duration, and treatment at the time 
of tissue sampling were recorded (Table 1). The duration 
of disease was defined as the time elapsed between clin-
ical diagnosis and the collection of thyroid tissue. The pa-
tients were divided into 2 subgroups according to disease 
duration: newly diagnosed GD (within the last 3 months) 
or chronic GD (median disease duration of 24  months). 
Thyroid tissue samples were collected by core needle bi-
opsy in patients with newly diagnosed disease, and from 
surgical specimens during thyroidectomy in patients with 
chronic disease. Thyroid tissue samples from 24 patients 
undergoing neck surgery for reasons other than AITD, 
such as thyroid tumors or parathyroid adenomas, served 
as controls. Control samples were taken from normal thy-
roid tissue adjacent to the pathological lesion. To insure 
no preexisting or unrecognized thyroid autoimmunity, we 
measured serum antibodies against thyroid peroxidase 
(TPO-Ab), thyroglobulin, and thyrotropin receptor (TRAb) 
in all control individuals.
Formalin-fixed, paraffin-embedded (FFPE) tissue sam-
ples were cut into 3-μm slices and mounted on slides for 
further analysis. The regional ethics committee approved 
the study and written informed consent was obtained from 
all participants.
Immunohistochemistry
HLA class I and VP1 immunostaining was performed with 
a standard IHC protocol in all samples. Antigens were 
unmasked by heating in 10-mM citrate buffer of pH 6.0, 
in a pressure cooker in a microwave oven (800 W) for 
20 minutes, followed by 20 minutes of cooling at room 
temperature. Sections were blocked with 10% goat serum 
and primary antibodies diluted in Dako REAL antibody 
diluent (Agilent S202230). The Dako antienteroviral VP1 
(5D8/1 clone) was used at a dilution of 1:1400 (55 ng/mL) 
for 30 minutes. The HLA class I primary antibody (Abcam 
class  I HLA [EMR8/5] Ab70328) was used at a dilution 
of 1:1500 for 1 hour. Primary antibodies were visualized 
using the Dako REAL EnVision Detection system (Agilent 
K5007).
Combined immunofluorescence
To examine the presence of STAT1 and PKR, and to test the 
localization of these proteins in relation to HLA class I and 
VP1 within the same FFPE sections, we performed com-
bined IF of STAT1/HLA class  I  and PKR/VP1. Owing to 
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antibody, we performed IF staining in a subset of the sam-
ples only. Seventeen samples of especially good quality and 
size were analyzed. Antigen retrieval and blocking were 
performed as described in the IHC protocol described 
earlier. The sections were immunostained sequentially 
with STAT1 (Ab109320, dilution 1:500, overnight pri-
mary incubation at 4 °C), followed by HLA class I (Abcam 
class I HLA [EMR8/5] Ab70328, dilution 1:1000, 1 hour at 
room temperature). The same subset of cases were stained 
for PKR (Abcam Ab32052 at a dilution of 1:700, overnight 
at 4 °C) and VP1 (Dako antienteroviral VP1 [5D8/1 clone], 
1:1000 dilution, overnight at 4  °C). Primary antibodies 
were detected using species-specific secondary antibodies 
(antirabbit or antimouse immunoglobulin  G [H + L]) 
conjugated to either Alexa Fluor 488 or Alexa Fluor 555 
(Invitrogen) at a dilution of 1:400 for 1 hour at room tem-
perature, together with DAPI 1:1000.
Image acquisition and analysis
Bright-field image acquisition and analysis were performed 
on a Nikon 50i microscope fitted with a DS-Fi camera 
and a DSL2 camera control unit. Images were captured 
and analyzed using the ImageJ platform. IF image collec-
tion and processing were achieved using a Leica DM4000 
B LED upright fluorescence microscope and Leica Image 
analysis software (LAS X).
Immunohistochemical analysis
The slides were analyzed by light microscopy at 400× magni-
fication by 2 independent scientists (T.W. and S.J.R.). Tissue 
samples were interpreted in a blinded fashion. First, samples 
were classified as positive or negative for HLA class I. Only 
immunostaining of thyroid follicular cells (thyrocytes) was 
evaluated. Next, HLA class  I  immunoreactivity was graded 
according to the semiquantitative Allred scoring system. The 
Allred scoring system takes both intensity (ranging from 0 to 
3) and proportion (ranging from 0 to 5)  into account, with 
8 being the maximum score possible and 0 being the lowest 
score. This system is commonly used in clinical settings to as-
sess the immunostaining of pathological specimens (33).
We assessed VP1 staining by counting all positively 
stained thyrocytes alongside the total number of thyrocytes 
in 10 consecutive counting grids (0.058 mm2) at 400× mag-
nification, thus yielding a percentage of positively stained 
thyrocytes.
Statistics
If normally distributed, continuous variables were summarized 
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and interquartile ranges (median [25th percentile to 75th per-
centile]). Categorical variables were summarized as frequencies 
and percentages. Statistical significance of differences between 
groups was calculated with the independent-samples t test if ful-
filling criteria of normality, and with the Mann-Whitney U test 
if not. The Pearson chi-square test was used to determine the 
statistical significance of differences in proportions. Associations 
between clinical features and results were explored using binary 
logistic regression, Pearson correlation for continuous data, and 
the Spearman correlation for ordinal data. All analyses were 
performed using IBM SPSS Statistics version 25 and GraphPad 
Prism 7.02. We considered P values less than .05 significant.
Results
Few studies have looked at the immunological tissue re-
sponses in GD thyroid tissue. In the present study, we found 
HLA class  I  upregulation and antiviral proteins both in 
recent-onset GD and chronic GD.
Study population
Thyroid samples from 26 patients with chronic GD, 22 pa-
tients with newly diagnosed GD, and 24 controls were ana-
lyzed. Patient characteristics and demographic data are 
presented in Table  1. All new GD samples were collected 
within 3 months after diagnosis, while the median disease dur-
ation before sampling was 24 months for chronic GD. None 
of the recent-onset GD patients received antithyroid treat-
ment prior to inclusion, whereas 23 out of 26 chronic GD 
patients were on antithyroid treatment (22 on carbimazole 
and 1 on propylthiouracil) at inclusion. The GD group was 
significantly younger (44.0 ± 13.1  years) than the control 
group (52.0 ± 14.4 years). Eighteen out of 44 (40.9%) GD pa-
tients and 5 out of 23 (21.7%) controls were current cigarette 
smokers (P = .119). Smoking status data was missing from four 
GD patients and one control. The sex distribution was equal 
in each group (87.5% female in GD and 91.7% female in the 
control group). Three patients in the GD group (6.3%) had 
one additional autoimmune disease (ankylosing spondylitis, 
Addison disease and Sjögren syndrome). Two patients in the 
control group (8.3%) had an autoimmune disease (ulcerous 
colitis and psoriasis). Ten chronic GD patients received steroids 
(methylprednisolone intravenously n = 6, prednisolone orally 
n = 4) due to Graves ophthalmopathy (GO).
Human leukocyte antigen class I is upregulated 
in Graves disease
HLA class I presents viral antigens to CD8+ T cells of the 
immune system and plays a vital role in the body’s de-
fense against virus. We herein demonstrate that HLA 
class I expression is significantly higher in GD compared to 
controls (Fig. 1A). First, we examined the number of posi-
tive samples in GD and controls. We found increased HLA 
class I expression in thyroid tissue in 25 of 48 (52.1%) sam-
ples in the GD group, but in only 5 of 24 (20.8%) samples 
in the control group (P = .011). The chronic GD group had 
a significantly higher number of HLA class I–positive sam-
ples than controls, with 15 of 26 (57.7%) being positive 
(P = .012) (Fig. 2A). The proportion of HLA class I–posi-
tive samples in the new GD group was also higher than in 
the control group (45.5% vs 20.8% respectively); however, 
the difference did not reach statistical significance. The pro-
portion of HLA class I–positive samples did not differ sig-
nificantly between the recent-onset and chronic GD group.
Next, we assessed HLA class I expression using an IHC 
scoring tool that takes both intensity and proportion of 
immunostaining into account (ranging from 0 to 8) (33). The 
mean HLA class I expression score was 3.1 ± 3.3 in GD pa-
tients and 0.5 ± 0.9 in controls (P < .001). Each subgroup had 
a significantly higher HLA class I expression score compared 
to the control group (3.4 ± 3.3 in chronic GD and 2.8 ± 3.3 
in new GD) (Fig. 2B). Additionally, when considering HLA 
class I–positive samples only (score ≥ 1), the HLA class I ex-
pression score differed significantly between GD patients 
(6.0 ± 1.7) and controls (2.2 ± 0.4) (P < .001). Moreover, no 
samples in the control group had an HLA class I expression 
score higher than 3. The HLA class I expression score did not 
significantly differ between the two GD subgroups.
The proportion of HLA class I–positive samples was slightly 
higher in the 10 patients who received steroids before study in-
clusion (60.0%) compared to the group that did not receive 
steroids (50.0%) (P = .578). Moreover, the HLA class I score 
was higher (4.0 ± 3.6) in the steroid group compared to the GD 
patients who did not receive steroids (2.9 ± 3.2) (P = 0.347).
Thyroid function (thyrotropin [TSH] and free thy-
roxine), TRAb level, age, smoking status, and duration 
of disease did not significantly influence or correlate with 
the proportion of HLA class  I–positive samples or HLA 
class  I  expression score. Although the mean TRAb was 
higher in the HLA class I–positive samples (17.7 ± 5.8 IU/L) 
than in the HLA class I–negative sample (9.3 ± 1.5 IU/L), 
the difference did not reach statistical significance.
Smoking increases the risk of GD, and especially GO, but 
several studies indicate that smoking protects against the devel-
opment of TPO-Ab and thyroglobulin antibodies (34-37). In 
the present study, the proportion of GD patients with positive 
TPO-Ab was not different between smokers and nonsmokers 
(68.4% vs 66.7%, respectively) (P = .907). The median 
TPO-Ab titer, however, was nonsignificantly lower in smokers 
compared to nonsmokers (124 vs 180 kIU/L) (P = .511). 
Smokers had a higher median thyroglobulin antibody titer 
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Signal transducer and activation of transcription 
1 is colocalized with human leukocyte antigen 
class I within thyroid cells
STAT1 is a cytoplasmic protein, which on activation by 
interferons translocates to the nucleus and initiates tran-
scription of antiviral response proteins. We analyzed 
STAT1 in relation to HLA class I expression in a subset of 
samples (4 with newly diagnosed GD, 9 chronic GD, and 
4 controls). Interestingly, we found elevated STAT1 in all 4 
GD samples with newly diagnosed disease and in only 3 of 
9 samples in the chronic GD group. Two of the 4 control 
samples were also positive (Table 2). STAT1 expression was 
colocalized with HLA class I, and we observed both cyto-
solic and nuclear STAT1 (Fig. 3A).
Enteroviral capsid protein 1 was detected in 
thyroid tissue
The presence of enterovirus can be explored by staining for the 
enteroviral capsid protein VP1 (38) (Figs. 1C and 3C). We pre-
viously reported both increased VP1 and the presence of entero-
virus RNA (in situ hybridization) in the same GD cohort (11). 
VP1 was found in more GD samples (29 of 48 [60.4%]) than in 
controls (10 of 24 [41.7%]). This difference was significant only 
when comparing chronic GD patients (19 of 26 [73.1%]) to con-
trol individuals (10 of 24 [41.7%]) (P = .025). When analyzing 
the VP1-positive samples, there were also significantly more VP1+ 
thyrocytes in the GD samples (median 40.0% [19.0%-80.9]) 
than in the controls (median 11.7% [7.7%-18.1%]) (P < .001) 
(Fig. 4A). The 2 disease stages differed in the numbers of VP1+ 
thyrocytes, with the chronic GD patients having a significantly 
higher number (median 70.4% [33.2%-91.5%]) than the newly 
diagnosed GD group (median 19.0% [16.3-35.4%]) (P = .003) 
(Fig. 4A). Finally, significantly more GD samples (20 out of 48 
[41.7%]) than control samples (2 out of 24 [8.3%]) (P = .004) 
were double positive (both VP1+ and HLA class I+ thyrocytes) 
(Fig. 4B).
VP1 and HLA class  I  expression score were posi-
tively correlated (Pearson correlation = 0.48, P < .001). 
Moreover, the odds of being HLA class I positive were 4.0 
times higher in the VP1-positive group compared to the 
VP1-negative group (P = .007).
Protein kinase R was colocalized with enteroviral 
capsid protein 1
The antiviral enzyme PKR inhibits viral messenger RNA trans-
lation, thus preventing viral replication. The transcription of 
PKR is positively regulated by STAT1. We detected PKR in 11 
Figure 1. Immunohistochemical staining for HLA class I and VP1 in thyroid tissue samples from GD patients and controls. HLA class I and VP1 was 
found in more GD samples than controls. A, Positive HLA class I staining (brown color) in thyroid follicular cells in a new GD sample. B, Negative 
HLA class I staining in a control sample. C, Globally positive VP1 staining (brown color) in thyroid follicular cells in a chronic GD sample. D, Negative 
VP1 staining in a control sample. All samples stained with a standard horseradish peroxidase immunohistochemistry protocol. GD, Graves disease; 
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out of 13 GD samples and in 1 out of 4 control samples (see 
Table 2). PKR was found in all new GD samples. Interestingly, 
PKR was colocalized with VP1 within the same thyroid cells 
(see Fig. 3C).
Plasmacytoid dendritic cells correlate with 
human leukocyte antigen class I
We previously reported an increased density of plasmacytoid 
dendritic cells (PDCs) and upregulated expression of the 
type 1 interferon downstream response protein myxovirus 
resistance protein A (MxA) in newly diagnosed GD (39). 
CD8+ T cells, on the other hand, were mainly found in 
chronic GD in this cohort (39). CD8+ T cells recognize the 
HLA class I–viral antigen complex, and induce destruction 
of virally infected cells. When combining previous results 
with current HLA class I findings, we found a significantly 
positive correlation between HLA class I score and density 
of number of PDCs in thyroid tissue (Pearson correlation 
0.332, P = .029). The number of VP1+ thyrocytes correlated 
with CD8+ T cells (Pearson correlation = 0.338, P = .012). 
Ten of 25 (40.0%) VP1-positive GD samples had CD8+ T 
cells, whereas only one of the 16 (6.3%) VP1-negative GD 
samples had CD8+ T cells (P = .017).
Discussion
In this study consisting of thyroid tissue samples both from 
newly diagnosed and chronic GD patients, we show that 
HLA class  I  upregulation is a prominent feature of GD. 
Moreover, HLA class I is colocalized with the antiviral im-
mune response protein STAT1, whereas the enterovirus 
capsid protein VP1 is colocalized with PKR, suggesting 
an active antiviral thyroid tissue immune response in GD. 
Additionally, we confirm earlier findings of VP1 in the same 
cohort, which was particularly prevalent in chronic GD 
tissue samples.
HLA class  I  was upregulated in thyroid cells both in 
chronic and new GD tissue samples. These findings are 
in line with the seminal work of Hanafusa and Bottazzo, 
who found upregulated HLA class I  in 16 out of 26 sur-
gical thyroid samples from GD patients (16). We found in-
creased HLA class I expression in 5 out of 24 controls, but 
the intensity and proportion of HLA class I staining were 
significantly lower in the control samples than in the GD 
samples.
Amplified HLA class I has been found in several auto-
immune diseases, with type  1 diabetes being the most 
studied (40). The role of the amplified HLA class  I  ex-
pression is, however, unknown. We hypothesize that the 
amplified HLA class I response is due to an active immune 
response following viral infection. Numerous theories on 
how viral infections can induce autoimmunity exist (re-
viewed in [41]). Infection leads to the production of in-
flammatory cytokines and expression of costimulators on 
antigen-presenting cells, thus attracting immune cells to the 
infected area and decreasing the threshold for self-attack. 
Interferon α, which is produced in large quantities by PDCs 
in viral infections, stimulates HLA class  I  upregulation 
(42) and induces thyroglobulin degradation (43), which 
is a potential mechanism for pathological thyroglobulin 
presentation. Moreover, infectious microbes may produce 
Figure 2. HLA class I immunodetection and HLA class I expression score. 
Significantly more HLA class  I–positive samples were found in the GD 
group than in the control group. A, Proportion of samples with HLA 
class I positivity in the 2 GD subgroups and in the controls. B, HLA class I 
expression score (Allred score), taking both immunostaining intensity and 
proportion of stained tissue into account (maximum score 8, and lowest 
score 0). The HLA class I expression score was significantly higher in the 
chronic GD group and in the newly diagnosed GD group than in controls. 
Bars represent mean and SD. *P less than or equal to .05; **P less than 
or equal to .01; *** P less than or equal to .001. GD, Graves disease; HLA, 
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antigens similar to self-antigens, thus evoking an im-
mune attack against the self. Proteins derived from in-
fectious agents, such as Borrelia burgdorferi and Yersinia 
enterocolitica, show structural homology with the TSH re-
ceptor (44). Furthermore, tissue injury might lead to the 
release of otherwise hidden antigens that can prompt an 
immune response. Finally, HLA class I upregulation might 
be a virus-evading strategy. HLA class  I  acts as a self-
tolerance checkpoint for natural killer cells. Some viruses, 
including hepatitis C virus, herpesvirus, and flavivirus, in-
duce upregulation of HLA class  I  to avoid natural killer 
cell–mediated attacks (45-47).
Antithyroid drugs and steroids both are immunosuppres-
sive, and a suppressive effect on HLA class I cannot be ruled 
out. However, we could not find any significant differences 
in HLA expression in participants treated with steroids or 
antithyroid drugs compared to those without any treatment.
Interestingly, Mack et al showed that orbital fibroblasts 
from GD patients expressed HLA class II in response to cig-
arette toxins in combination with interferon γ stimulation 
(48). The increased capacity of antigen presentation due to 
smoking and interferon γ, which is a viral response cyto-
kine, might be one of the reasons that smokers are more 
prone to develop GO. However, no such association has 
been shown for HLA class I expression and GO. We found 
more HLA class  I–positive samples and a higher HLA 
class I score in smoking GD patients, but the difference did 
not reach statistical significance.
Viral infections have been linked to several autoimmune 
diseases, and there is evidence of persistent enterovirus in-
fection of the β cells of the pancreas in patients with type 
1 diabetes (12, 13). Enteroviruses, among other viruses, 
have also been associated with AITD (4-11). In patients 
genetically predisposed for AITD, an additional AITD-
susceptibility gene was expressed when exposed to prod-
ucts of microbial infection (49). This interplay of genetic 
predisposition and infectious insults could explain why 
common infections give rise to autoimmunity in some but 
are negligible in others. To perform double staining for 
VP1 and antiviral tissue markers, we first repeated VP1 
staining and found similar results as previously reported 
(11). Immunoreactive VP1 was present in thyroid sam-
ples from GD patients and controls, but significantly more 
VP1 was found in GD patients than in control individuals. 
Notably, the chronic GD tissue samples had remarkably 
high VP1 numbers. Moreover, the positive correlation be-
tween VP1 and HLA class I might indicate that the HLA 
class I upregulation is a response to enterovirus infection. 
Interestingly, we previously confirmed the presence of the 
SIV isoform of the coxsackie and adenovirus receptor in 
thyroid tissue, thus proving that thyroid cells are suscep-
tible to enteroviral infection (22).
STAT1 was detected with an antiserum that does not dis-
criminate between phosphorylated and nonphosphorylated 
STAT1. However, the active, phosphorylated form of STAT1 
relocates from the cytosol to the nucleus. We identified 
Table 2. Sequential immunofluorescence in a subset of samples
 HLA class I STAT 1 PKR VP1
Chronic GD 1 Positive Negative Negative Negative
Chronic GD 2 Positive Positive Positive Positive
Chronic GD 3 Positive Negative Positive Positive
Chronic GD 4 Negative Negative Positive Positive
Chronic GD 5 Positive Negative Positive Positive
Chronic GD 6 Positive Positive Positive Positive
Chronic GD 7 Negative Negative Negative Negative
Chronic GD 8 Negative Negative Positive Positive
Chronic GD 9 Positive Positive Positive Positive
New GD 1 Positive Positive Positive Positive
New GD 2 Positive Positive Positive Positive
New GD 3 Positive Positive Positive Positive
New GD 4 Positive Positive Positive Positive
Control 1 Positive Positive Positive Positive
Control 2 Positive Positive Negative Negative
Control 3 Negative Negative Negative Negative
Control 4 Negative Negative Negative Negative
Seventeen samples were stained sequentially with immunofluorescence for HLA class I, STAT1, PKR, and VP1. The table shows that the majority of the GD samples 
were both HLA class I and STAT1 positive (shown in bold). All new GD samples stained positively for all proteins studied.
Abbreviations: GD, Graves disease; HLA, human leukocyte antigen; PKR, protein kinase R; STAT1, signal transducer and activator of transcription 1; VP1, 
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both cytosolic and nuclear STAT1, suggesting the presence 
of both inactive and active forms of STAT1 (see Fig. 3A). 
We found that STAT1 colocalized with HLA class I, thus 
supporting the previously proven link between activated 
STAT1 and upregulated HLA class  I  (23). The antiviral 
protein PKR, which is enhanced by STAT1 activation, 
was also found in the GD samples. PKR was colocalized 
within the same thyroid cells as VP1, thus demonstrating 
that enterovirus infection may lead to PKR expression (see 
Fig. 3C). This response resembles that of studies in which 
infection of thyrocytes or stimulation of cells with viral 
products caused upregulation of HLA class I, PKR, STAT1, 
and toll-like receptor 3, among other immune proteins (4, 
10, 50).
All recent-onset GD analyzed for STAT1 and PKR were 
positive, suggesting an active, interferon-driven immune 
Figure 3. Combined immunofluorescence of HLA class I/STAT1 and PKR/VP1 in GD samples and controls. Nuclear and cytosolic STAT1 was found 
in thyroid cells and was colocalized with HLA class I. PKR and VP1 were also colocalized within thyroid cells. A, An example of STAT1 (green) and 
HLA class I (red) immunofluorescence staining in GD thyroid tissue. Arrows indicate thyroid cells with nuclear STAT1 and intracellular HLA class I. B, 
Control sample with negative STAT1 and HLA class I staining. C, An example of VP1 (green) and PKR (red) immunofluorescence staining in GD thy-
roid tissue. The insets represent higher magnification (of the area outlined by the white boxes) and shows colocalized VP1 and PKR within thyrocytes. 
D, Control sample with negative VP1 and PKR staining. Merged images with blue nuclear DAPI staining. All scale bars at 25 μm. DAPI, 4’,6-diamidino-
2-phenylindole; GD, Graves disease; HLA, human leukocyte antigen; PKR, protein kinase R; STAT1, signal transducer and activator of transcription 
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response. Moreover, we confirmed that the chronic GD 
participants had more VP1+ thyroid cells. These findings 
are consistent with our previous results, which also showed 
an interferon-driven response in recent-onset GD. PDCs, 
which secrete type 1 interferon in the presence of virus, 
were prevalent in recent-onset GD tissue. Likewise, the 
type 1 interferon surrogate marker MxA was also prom-
inent in recent-onset GD (39). CD8+ T cells, on the other 
hand, were characteristic of chronic GD (39). When com-
bining results from these previous analyses performed in 
the same cohort, our findings point to an acute antiviral 
response in recent-onset GD and a persistent viral infection 
in chronic GD.
We show some important differences between chronic 
and new GD, hypothesizing that these 2 patient groups 
might differ in their ability to resolve viral infection. 
However, our method of detecting enterovirus is not suit-
able to answer whether the VP1 represents persistent or 
acute infection. As well as applying other methods, this 
hypothesis should be addressed with a different study de-
sign, allowing thyroid tissue biopsies in a study popula-
tion at several time points. Moreover, new technologies 
that allow us to target the peptide-binding capacities of 
the HLA molecules could provide answers as to what 
thyroid cells are presenting (51). Furthermore, novel 
methods could be applied to characterize the specific 
T-cell response in adaptive immunity (52). Finally, more 
sensitive methods than IHC should be applied to confirm 
the presence of virus in thyroid tissue in autoimmune thy-
roid diseases. Yet, the timing in break of tolerance and 
debut of clinical manifestations in autoimmune diseases 
are difficult to establish.
In conclusion, we report HLA class I hyperexpression in 
thyroid tissue from a large GD cohort consisting both of 
recent-onset and chronic GD. Additionally, we found the 
immune response protein STAT1 colocalized with HLA 
class  I  and VP1 with PKR, which is indicative of an ac-
tive, antiviral host response. These results are similar to 
our recently reported findings in Hashimoto thyroiditis, 
demonstrating common features in AITD. Moreover, we 
confirm the presence of VP1 both in chronic and new GD, 
with VP1 being especially evident in chronic GD. Taken 
together with earlier reports of MxA, PDCs, and CD8+ T 
cells in the same tissue samples, we believe our study adds 
evidence to the theory of a link between enterovirus and 
thyroid autoimmunity.
Strengths and Limitations
The thyroid tissue cohort used in this study is unique be-
cause of its considerable proportion of newly diagnosed 
GD patients. Moreover, the cohort is large when taking into 
consideration the limited access to thyroid tissue, especially 
at the onset of disease. However, this study has several limi-
tations. The size of the control group was limited. We did 
not analyze PKR and STAT1 in all samples. Moreover, the 
tissue samples from the chronic GD patients were larger 
in size because they were taken from surgical specimens. 
Figure 4. VP1 assessment in GD samples and controls. We confirmed 
the presence of VP1 in GD samples. A, Number of VP1+ thyrocytes in 
the GD subgroups and controls. There were significantly more VP1+ 
thyrocytes both in the chronic GD group and the new GD group com-
pared to controls. The chronic GD group had significantly more VP1+ 
thyrocytes than the new GD group. Bars represent median and inter-
quartile range. B, Proportion of double-positive samples (VP1+/HLA I+) 
in the GD group and the controls. We found significantly more double-
positive samples in the GD group than in the control group. *P less 
than or equal to .05; **P less than or equal to .01; ***P  less than or 
equal to .001. GD, Graves disease; HLA, human leukocyte antigen; VP1, 
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However, when counting the VP1+ cells, a fraction based on 
the total number of cells in the tissue sample was used and 
the proportion of positively stained thyrocytes was used in 
the HLA class I expression score.
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